CONTEXT: Duke University researchers have shown that a test assessing functional and morphologic information gathered during contrast-enhanced MRI renders a score that accurately predicts the response of nine of 10 breast cancer cases to neoadjuvant chemotherapy.
RESULTS: T1-weighted imaging was performed in 20 women with locally advanced breast cancer. Principal investigator Oana Craciunescu, Ph.D., an assistant clinical professor of radiation oncology at Duke, studied the characteristics of tumor perfusion, permeability, and morphology/cellularity. Highly vascular tumors with efficient vascular systems carried more tracer and chemotherapy than tumors fed by less efficient vessels. Homogeneous tumors with an even distribution of blood vessels responded best to therapy. Tumors with densely packed cancer cells did not effectively retain the tracer and responded poorly.
Tumors featuring an equatorial ring of blood vessels also tended to resist chemotherapy because of collapsed vessels.
IMAGE: Morphophysiological tumor scores based on a five-point scale were calculated for a responder (top) and a nonresponder (bottom) to chemotherapy performed before surgery. Enhancement curves revealed the tumor's washin (WiP), washout (WoP), and centripetal (CP) and centrifugal (CF) characteristics. WiP measured the mass's vascularity, permeability, and homogeneity. Tumors with an inhomogeneous pattern or ring enhancement were classified as CP. Tumors with a homogeneous pattern were classified as CF. WoP correlated with tumor cellularity.
IMPLICATIONS: Poor responders identified by this technique can be referred directly to surgery, thereby avoiding the discomfort of chemotherapy. The method will be tested at Duke in a larger trial of patients with locally advanced breast cancer.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.